8 results about "Integrin ligand" patented technology

The present invention relates to an integrin ligand key intermediate and a preparation method therefor, and specifically provides a new process for synthesizing target compound (7). Compared with existing synthesis processes, the new synthesis process can avoid racemic intermediate compound resolution, improve yields and reduce costs, thereby strongly supporting cost reduction and large-scale production of an αvβ6 integrin ligand.

The invention provides a compound as shown in the following formula I, a tautomer or pharmaceutically acceptable salt thereof, and the compound has serum stability and affinity to integrin alpha v beta 6, has a better alpha v beta 6 integrin inhibition effect, and further has an inhibition effect on tumor growth.

The present invention provides double stranded ribonucleic acid (dsRNA) agents for inhibiting expression of a target gene, comprising an antisense strand which is complementary to the target gene; a sense strand which is complementary to the antisense strand and forms a double stranded region with the antisense strand; and at least one alpha-v-beta-6 (αvβ6) integrin targeting ligand that mediates delivery to an extrahepatic tissues, e.g., muscle tissue, e.g., skeletal muscle tissue and / or cardiac muscle tissue, or lung tissue, conjugated to at least one strand, compositions comprising such dsRNA agents, and methods of use thereof for treating a subject having a disorder that would benefit from reduction in expression of the target gene. The dsRNA may optionally contain an in vivo delivery enhancing agent.

Provided herein are α4β1 / 7 integrin receptor ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using said compounds.

This document provides compounds comprising a delivery portion for selectively delivering a therapeutic agent and / or oligonucleotide to the lungs. This document also provides compounds comprising a single delivery portion for selectively delivering a therapeutic agent and / or oligonucleotide to the lungs. This document also discloses novel α- v β x Integrin ligands, such as those with α v β5, α v β6 and / or α v Ligands that bind to β8 integrin.

The present invention provides double stranded ribonucleic acid (dsRNA) agents for inhibiting expression of a target gene, comprising an antisense strand which is complementary to the target gene; a sense strand which is complementary to the antisense strand and forms a double stranded region with the antisense strand; and at least one alpha-v-beta-6 (αvβ6) integrin targeting ligand that mediates delivery to an extrahepatic tissues, e.g., muscle tissue, e.g., skeletal muscle tissue and / or cardiac muscle tissue, or lung tissue conjugated to at least one strand, compositions comprising such dsRNA agents, and methods of use thereof for treating a subject having a disorder that would benefit from reduction in expression of the target gene.

The present invention provides double stranded ribonucleic acid (dsRNA) agents for inhibiting expression of a target gene, comprising an antisense strand which is complementary to the target gene; a sense strand which is complementary to the antisense strand and forms a double stranded region with the antisense strand; and at least one alpha-v-beta-6 (αvβ6) integrin targeting ligand that mediates delivery to an extrahepatic tissues, e.g., muscle tissue, e.g., skeletal muscle tissue and / or cardiac muscle tissue, or lung tissue, conjugated to at least one strand, compositions comprising such dsRNA agents, and methods of use thereof for treating a subject having a disorder that would benefit from reduction in expression of the target gene. The dsRNA may optionally contain an in vivo delivery enhancing agent.

Integrin ligands having serum stability and affinity for avß6 integrins are described. Compositions comprising avß6 integrin ligands having serum stability and having affinity for avß6 integrins and methods of using them are also described. 20 24 20 26 95 24 A pr 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 6 9 5 2 4 2 0 2 4 A p r